While reduced food intake has long been considered the dominant driver of GLP1RAinduced weight loss, this explanation might not fully capture the breadth of biological adaptations observed with GLP1 analogue treatment
Currently recommended pharmacotherapies in the practice guidelines from US, Europe, and Japan Evidence-based practice guidelines for the management of NASH/NAFLD were published by the American Association for the Study of Liver Disease (AASLD) in 2012 [5], the Japan Society of Gastroenterology (JSG)Japan Society of Hepatology (JSH) in 2014 [6], and the European Association for the Study of the Liver (EASD)European Association for the Study of Diabetes (EASL)European Association for the Study of Obesity (EASO) in 2016 [7]
Studies show that with long-term use, people can maintain this weight loss for years, though you need to continue to take the medication
Common side effects noted in clinical trials included: The manufacturer currently advises patients to seek urgent advice if they experience: You shouldn't take Wegovy pills if you: Tell your prescriber before starting if you: Always inform your prescriber about any medications you're taking, including prescription medicines, over-the-counter treatments, and vitamins and supplements
More persistent effects related to dopamine and serotonin receptor changes may last through the first three to six months
